Study comparing dexamethasone versus immunoglobulin plus prednisone for adults with immune thrombocytopenia (ITP) who have moderate to severe bleeding

3 1 1 1

What is this study about?

This study focuses on adults with Immune Thrombocytopenia (ITP), a condition where the immune system attacks blood platelets, leading to bleeding problems. The research compares two different treatment approaches for patients experiencing mild to severe bleeding symptoms. The purpose is to determine if one treatment method works as effectively as the other.

The first treatment combination consists of intravenous immunoglobulin given through a vein along with oral prednisone tablets taken daily for three weeks. The second treatment option involves high-dose dexamethasone tablets taken for four days. Both treatments aim to increase the number of platelets in the blood and reduce bleeding symptoms.

The study will track how quickly patients respond to treatment over the first five days, particularly looking at improvements in platelet counts and reduction in bleeding. Patients will be monitored for six months to evaluate the long-term effectiveness of both treatments. Throughout the study, doctors will regularly check platelet counts and assess any bleeding symptoms.

1 Initial treatment – Group 1

If assigned to the first treatment group, you will receive intravenous immunoglobulin (IVIg) at 1g/kg on days 1 and 2, combined with prednisone tablets at 1 mg/kg daily for 3 weeks

The medication will be given through an intravenous line (directly into your vein) in a medical setting

2 Initial treatment – Group 2

If assigned to the second treatment group, you will receive dexamethasone tablets at 40 mg daily on days 1 through 4

The medication will be taken by mouth according to the prescribed schedule

3 Initial monitoring period

Your blood platelet count will be monitored during the first 5 days of treatment

Medical staff will check for any signs of bleeding

Your response to treatment will be evaluated based on your platelet count reaching 30,000 or higher per microliter of blood

4 Follow-up period – First month

Your condition will be monitored for 28 days after starting treatment

Medical staff will track any bleeding episodes

Blood tests will be performed to check your platelet count

5 Long-term follow-up

Your condition will be monitored for a total of 6 months

Regular blood tests will continue to check your platelet count

Any side effects or bleeding episodes will be recorded

Who Can Join the Study?

  • Must be between 18 and 80 years old
  • Must have been diagnosed with immune thrombocytopenia (ITP) – a condition where the immune system attacks blood platelets, either newly diagnosed or recurring
  • Must have a platelet count equal to or below 20 x 109/L (platelets are blood cells that help with blood clotting)
  • Must have visible signs of bleeding, either:
    • on the skin (cutaneous bleeding), and/or
    • on mucous membranes (such as inside mouth, nose, or other body cavities)
  • Must be registered with a social security system
  • Must be able and willing to provide written informed consent to participate in the study

Who Cannot Join the Study?

  • Patients under 18 years old (minors)
  • Patients with active or chronic infections (ongoing illnesses caused by bacteria, viruses, or other microorganisms)
  • Those with uncontrolled high blood pressure (hypertension)
  • Patients with active peptic ulcers (open sores in stomach or small intestine)
  • People with uncontrolled diabetes (unstable blood sugar levels)
  • Patients with known hypersensitivity (allergic reactions) to dexamethasone, prednisone, or IVIg
  • Pregnant or breastfeeding women
  • Patients with severe liver disease (conditions affecting liver function)
  • Those with severe kidney disease (conditions affecting kidney function)
  • Patients with active malignancy (cancer currently requiring treatment)
  • Those participating in other clinical trials
  • Patients unable to provide informed consent
  • Individuals with history of blood clotting disorders
  • Those with severe cardiovascular disease (serious heart conditions)

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Oncopole Claudius Regaud Toulouse France
University Hospital Of Clermont-Ferrand Clermont Ferrand France
Centre Hospitalier Intercommunal Creteil Creteil France
Centre Hospitalier Universitaire De Bordeaux Bordeaux France
Centre Hospitalier Universitaire De Lille Lille France
Centre Hospitalier Regional Et Universitaire De Brest Brest France
CHU Grenoble Alpes La Tronche France

Other Sites

Site Name City Country Status
Centre Hospitalier Victor Dupouy Argenteuil France
Centre Hospitalier Universitaire Rouen Rouen France
Hospital Foch Suresnes France
Centre Hospitalier Universitaire De Poitiers Poitiers France
Centre Hospitalier D Avignon Avignon France
Centre Hospitalier Sud Francilien Corbeil Essonnes France
Centre Hospitalier Universitaire De Nantes Nantes France
Hopital Saint Joseph Marseille France
Centre Hospitalier Bretagne Atlantique Vannes France
Centre Hospitalier Universitaire Amiens Picardie Amiens France
Centre Hospitalier Lyon Sud Pierre Benite France
Hopital Beaujon Clichy France
Centre Hospitalier Universitaire De Caen Normandie Caen France
Centre Hospitalier Intercommunal De Poissy Saint Germain St Germain En Laye France
Centre Hospitalier Saint Nazaire St Nazaire France
Crbgxv Hiitajorxuv Ukqfziwqxurmf Rahrv Reims France
Chjkeg Hfvclsdkbjs Urplvkpxsshhe Ds Dfawd Dijon France
Afasswxavw Pjrqcxbx Hvijrxgr Dg Mfwyhvzae Marseille France
Besxdogz Uzptmuwuph Huhokhnp Cemmtk Besançon France
Cajj Ds Nvptb Vandoeuvre Les Nancy France
Cubctw Hzrntyffbnr Rqepmhxg Domezcxeicslzo Angers France
Itpqbukc dv Caufrgwkyflo Hdytkdjmihd Uclzwsxrdddln da Smffl Evnklis (zqmzpoc Saint Priest En Jarez France
Hkzwsnut Ugglhndjrcljbl Shspjqjmmt &mnixqm Hqvgnqx dr Hooxkfsvdol STRASBOURG, Alsace France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Not recruiting
07.04.2022

Trial locations

Intravenous Immunoglobulin (IVIg) is a medication made from donated blood plasma that contains antibodies. It helps boost the immune system and is commonly used to treat immune disorders. In this trial, it’s used to help increase platelet counts in patients with immune thrombocytopenia (ITP), a condition where the body’s immune system attacks its own platelets.

Prednisone is an oral steroid medication that helps reduce inflammation and suppress the immune system. It’s commonly used to treat various autoimmune conditions, including ITP, by preventing the immune system from destroying platelets.

Dexamethasone is a potent steroid medication that, like prednisone, works to suppress the immune system and reduce inflammation. It’s often used as an alternative to prednisone in treating ITP and other autoimmune conditions. This medication is typically taken orally and can help increase platelet counts by preventing the immune system from attacking platelets.

Immune Thrombocytopenia (ITP) – A blood disorder where the immune system mistakenly attacks and destroys platelets, which are blood cells needed for normal blood clotting. The condition causes lower than normal platelet counts in the blood, which can result in easy bruising and bleeding. ITP can develop suddenly or gradually, and it may occur after a viral infection or other triggering event. The severity of symptoms can vary among individuals, with some experiencing mild bruising while others may have more noticeable bleeding manifestations. In adults, ITP often becomes a chronic condition that can persist for months or years.

Trial ID:
2024-516403-16-00
Protocol code:
APHP200017
NCT ID:
NCT04968899
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • A Study to Test How Safe Budoprutug Is and How Well It Works in Patients with Immune Thrombocytopenia

    Recruiting

    1 1 1
    Investigated drugs:
    Bulgaria Greece Spain
  • A Follow-up Study of Mezagitamab in Adults with Chronic Primary Immune Thrombocytopenia to Evaluate Long-term Safety and Effectiveness

    Recruiting

    3 1 1
    Bulgaria Croatia Czechia France Germany Greece +6